Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 20/20 | 0.64 |
| ▸ | CNR1 | P21554 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3979588 | 0.90 | CNR2 (0.63) | CNR2CNR1KCNH2 | |
| SCHEMBL585319 | 0.86 | CNR2 (0.61) | CNR2CNR1KCNH2 | |
| SCHEMBL5181379 | 0.85 | CNR2 (0.66) | CNR2CNR1KCNH2 | |
| SCHEMBL4968683 | 0.85 | CNR2 (0.59) | CNR2CNR1 | |
| SCHEMBL3916373 | 0.85 | CNR2 (0.69) | CNR2CNR1KCNH2 | |
| SCHEMBL585337 | 0.84 | CNR2 (0.56) | CNR2CNR1 | |
| SCHEMBL5434787 | 0.84 | CNR2 (0.49) | CNR2CNR1KCNH2 | |
| SCHEMBL4968426 | 0.84 | CNR2 (0.65) | CNR2CNR1KCNH2 | |
| SCHEMBL4459897 | 0.83 | CNR2 (0.66) | CNR2CNR1 | |
| SCHEMBL585606 | 0.83 | CNR2 (0.69) | CNR2CNR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1797077-B1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF I | ASTRAZENECA AB (SE) | 2012-02-15 | — | — | EP | disclosed |
| US-20070072853-A1 | Benzimidazole derivatives compositions containing them, preparation thereof and uses thereof | ASTRAZENECA AB (SE) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072853-A1 | Benzimidazole derivatives compositions containing them, preparation thereof and uses thereof | RB1, CYP2C19, ADRB3 | CNR2 202/4885CNR1 182/4885KCNH2 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.